To the full analysis
GoodRx Holdings stock: growth
GDRXGoodRx Holdings reported $796.85M in revenue for fiscal 2025, up 0.6% on the prior year, up 7.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
26%
per year from 2016 to 2025, per share 27.1%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2016 | |
|---|---|---|
| Revenue | 7.7% | 26.0% |
| Revenue per share | 2.2% | 27.1% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | 11.5% | no data |
| Free cash flow per share | 5.8% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2016 | $99.38M | −$7.77M | $0 |
| 2017 | $157.24M | $8.84M | $0 |
| 2018 | $249.52M | $43.79M | $41.8M |
| 2019 | $388.22M | $66.05M | $77.54M |
| 2020 | $550.7M | −$293.62M | $95.52M |
| 2021 | $745.42M | −$25.25M | $144.32M |
| 2022 | $766.55M | −$32.83M | $91.57M |
| 2023 | $750.27M | −$8.87M | $82.53M |
| 2024 | $792.32M | $16.39M | $113.55M |
| 2025 | $796.85M | $30.44M | $164.38M |
Revenue by segment
How GoodRx Holdings, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Prescription Transactions Revenue73%
- Subscription Revenue11%
- Other16%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2021 | 2022 | 2023 | 2024 | Share 2024 | |
|---|---|---|---|---|---|
| Prescription Transactions Revenue | $593.36M | $550.54M | $550.74M | $577.55M | 72.9% |
| Subscription Revenue | $59.93M | $96.17M | $94.41M | $86.54M | 10.9% |
| Other | $92.14M | $119.85M | $105.12M | $128.24M | 16.2% |
| Total revenue | $745.42M | $766.55M | $750.27M | $792.32M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Jul 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.